DK120091D0 - Tripelstrenget nukleinsyre og anvendelse heraf - Google Patents
Tripelstrenget nukleinsyre og anvendelse herafInfo
- Publication number
- DK120091D0 DK120091D0 DK911200A DK120091A DK120091D0 DK 120091 D0 DK120091 D0 DK 120091D0 DK 911200 A DK911200 A DK 911200A DK 120091 A DK120091 A DK 120091A DK 120091 D0 DK120091 D0 DK 120091D0
- Authority
- DK
- Denmark
- Prior art keywords
- synthetic oligonucleotides
- dna
- bind
- duplex
- target sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01034—Hydroxymethylglutaryl-CoA reductase (NADPH) (1.1.1.34)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01018—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28735988A | 1988-12-20 | 1988-12-20 | |
PCT/US1989/005769 WO1990006934A1 (en) | 1988-12-20 | 1989-12-20 | Triple stranded nucleic acid and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
DK120091A DK120091A (da) | 1991-06-20 |
DK120091D0 true DK120091D0 (da) | 1991-06-20 |
Family
ID=23102554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK911200A DK120091D0 (da) | 1988-12-20 | 1991-06-20 | Tripelstrenget nukleinsyre og anvendelse heraf |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0375408B1 (de) |
JP (1) | JPH04502407A (de) |
AT (1) | ATE118818T1 (de) |
AU (1) | AU640910B2 (de) |
CA (1) | CA2006008C (de) |
DE (1) | DE68921315T2 (de) |
DK (1) | DK120091D0 (de) |
ES (1) | ES2069598T3 (de) |
PT (1) | PT92640B (de) |
WO (1) | WO1990006934A1 (de) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422251A (en) * | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
US5928863A (en) * | 1986-11-26 | 1999-07-27 | Princeton University | Triple-stranded nucleic acids |
US5849482A (en) * | 1988-09-28 | 1998-12-15 | Epoch Pharmaceuticals, Inc. | Crosslinking oligonucleotides |
US5721218A (en) * | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
US5399676A (en) * | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
IE20010427A1 (en) * | 1990-04-10 | 2003-03-05 | Canji Inc | Gene therapy for cell proliferative diseases |
WO1991018997A1 (en) * | 1990-05-25 | 1991-12-12 | Gilead Sciences, Inc. | Sequence-specific nonphotoactivated crosslinking agents which bind to the major groove of duplex dna |
EP0463712A3 (en) * | 1990-06-27 | 1992-04-08 | University Patents, Inc. | Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections |
US5734022A (en) * | 1990-08-01 | 1998-03-31 | The Johns Hopkins University | Antibodies to a novel mammalian protein associated with uncontrolled cell division |
EP0558634A4 (en) * | 1990-11-23 | 1995-06-28 | Gilead Sciences Inc | Triplex-forming oligomers containing modified bases |
EP0566670A4 (en) * | 1990-12-17 | 1993-12-08 | Idexx Laboratories, Inc. | Nucleic acid sequence detection by triple helix formation |
US5683874A (en) * | 1991-03-27 | 1997-11-04 | Research Corporation Technologies, Inc. | Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence |
US6136601A (en) * | 1991-08-21 | 2000-10-24 | Epoch Pharmaceuticals, Inc. | Targeted mutagenesis in living cells using modified oligonucleotides |
EP0672171A4 (de) * | 1991-08-30 | 1997-04-09 | Univ Johns Hopkins | Bildung von tripelhelixkomplexen aus doppelsträngiger dna mittels nukleotidoligomeren, die aus analogen purinbasen bestehen. |
IL103311A0 (en) * | 1991-10-07 | 1993-03-15 | Univ Johns Hopkins | Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers |
WO1993009127A1 (en) * | 1991-11-07 | 1993-05-13 | Gilead Sciences, Inc. | Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs |
US5594121A (en) * | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
DE69232816T2 (de) * | 1991-11-26 | 2003-06-18 | Isis Pharmaceuticals Inc | Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen |
TW393513B (en) * | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5484908A (en) * | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
US5616461A (en) * | 1992-05-14 | 1997-04-01 | Dana-Farber Cancer Institute | Assay for antiviral activity using complex of herpesvirus origin of replication and cellular protein |
US6403302B1 (en) | 1992-09-17 | 2002-06-11 | California Institute Of Technology | Methods and compositions for triple helix formation |
WO1994007367A1 (en) * | 1992-09-29 | 1994-04-14 | Apollon, Inc. | Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids |
EP0674705A4 (de) * | 1992-11-09 | 1997-11-26 | Univ Jefferson | Antisense-oligonukleotide zur hemmung der expression mutierter gene und wildtypgene des collagens. |
WO1994013793A1 (en) * | 1992-12-04 | 1994-06-23 | Apollon, Inc. | Compounds and methods for the treatment of leukemias |
IL107934A0 (en) * | 1992-12-08 | 1994-04-12 | Genta Inc | Formation of triple helix complexes |
AU6296294A (en) | 1993-01-26 | 1994-08-15 | Microprobe Corporation | Bifunctional crosslinking oligonucleotides adapted for linking to a desired gene sequence of invading organism or cell |
US6323185B1 (en) | 1993-04-23 | 2001-11-27 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-viral guanosine-rich oligonucleotides and method of treating HIV |
US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
US6288042B1 (en) | 1993-04-23 | 2001-09-11 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich tetrad forming oligonucleotides |
JP2798305B2 (ja) | 1993-06-23 | 1998-09-17 | ジェネシス ファーマ インコーポレイテッド | アンチセンスオリゴヌクレオチドおよびヒト免疫不全ウイルス感染におけるその使用 |
US5962426A (en) | 1993-06-25 | 1999-10-05 | Yale University | Triple-helix forming oligonucleotides for targeted mutagenesis |
ATE161541T1 (de) * | 1993-06-25 | 1998-01-15 | Univ Yale | Chemische-modifizierte oligonukleotide für site- spezifisches mutagenesis |
CA2174425A1 (en) * | 1993-10-18 | 1995-04-27 | Graham Leslie Barrett | A method for enhancing neurone survival and agents useful for same |
US5602109A (en) * | 1994-01-10 | 1997-02-11 | Abbott Laboratories | Method to enhance the immune system of a human |
US5700590A (en) * | 1994-01-10 | 1997-12-23 | Abbott Laboratories | Nutritional formula with ribo-nucleotides |
US5488039A (en) * | 1994-01-10 | 1996-01-30 | Abbott Laboratories | Method for the production of an enteral formula containing ribo-nucleotides |
US6136858A (en) | 1994-01-10 | 2000-10-24 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
US5492899A (en) * | 1994-01-10 | 1996-02-20 | Abbott Laboratories | Infant nutritional formula with ribo-nucleotides |
US5780611A (en) * | 1995-09-15 | 1998-07-14 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
US6156513A (en) * | 1995-09-15 | 2000-12-05 | Ramareddy V. Guntaka | Oligmers which inhibit expression of collagen genes |
US5808037A (en) * | 1995-09-15 | 1998-09-15 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
FR2746412B1 (fr) * | 1996-03-21 | 1998-06-12 | Rhone Poulenc Rorer Sa | Purification d'adn plasmidique de qualite pharmaceutique |
US6312925B1 (en) | 1997-05-08 | 2001-11-06 | Epoch Pharmaceuticals, Inc. | Methods and compositions to facilitate D-loop formation by oligonucleotides |
US6930175B1 (en) | 1997-12-12 | 2005-08-16 | The Johns Hopkins University School Of Medicine | Gene family with transformation modulating activity |
US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
ES2296615T3 (es) * | 1999-04-08 | 2008-05-01 | Antisoma Research Limited | Actividad antiproliferativa de oligonucleotidos ricos en g y procedimiento de uso de los mismos para su union a la nucleolina. |
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
FR2822156A1 (fr) * | 2001-03-16 | 2002-09-20 | Centre Nat Rech Scient | Oligonucleotides pour la regulation du gene codant pour le tnf alpha et/ou de genes sous son controle et leurs applications |
WO2004111183A2 (en) | 2003-06-19 | 2004-12-23 | Evogene Ltd. | Plant trichome-specific promoter and leucoplast signal sequence |
US8129514B2 (en) | 2003-06-19 | 2012-03-06 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
CN101273130B (zh) | 2005-07-07 | 2012-05-30 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 用于下调h19的核酸物质及其使用方法 |
US8658608B2 (en) | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
WO2008087641A2 (en) | 2007-01-16 | 2008-07-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
CA2696833A1 (en) | 2007-07-15 | 2009-01-22 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
HUE025283T2 (en) | 2007-08-02 | 2016-03-29 | Gilead Biologics Inc | LOX and LOX2 inhibitors and their use |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
WO2009124150A2 (en) | 2008-04-01 | 2009-10-08 | Biosearch Technologies, Inc. | Stabilized nucleic acid dark quencher-fluorophore probes |
US8962580B2 (en) | 2008-09-23 | 2015-02-24 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
WO2010113096A1 (en) | 2009-03-30 | 2010-10-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
WO2011022667A2 (en) | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | Catalytic domains from lysyl oxidase and loxl2 |
CA2770276A1 (en) | 2009-08-21 | 2012-02-24 | Beeologics, Inc. | Preventing and curing beneficial insect diseases via plant transcribed molecules |
EP2475381A2 (de) | 2009-09-08 | 2012-07-18 | Yeda Research and Development Co. Ltd. | Verfahren zur mobilisierung eines hämatopoetischen vorläufers |
US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
WO2011045796A1 (en) | 2009-10-14 | 2011-04-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions for controlling varroa mites in bees |
AU2011212830B2 (en) | 2010-02-04 | 2014-05-22 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor |
EP2561356B1 (de) | 2010-04-18 | 2016-08-03 | Yeda Research and Development Co. Ltd. | Moleküle und deren verwendung zur behandlung von erbb/erbb liganden - assozierten krankheiten |
US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
WO2011133876A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
WO2011158243A2 (en) | 2010-06-16 | 2011-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of diagnosing and treating cancer |
CN103210082A (zh) | 2010-09-15 | 2013-07-17 | 雷蒙特亚特特拉维夫大学有限公司 | 扩增胰岛β细胞和使其再分化的方法 |
EP2627766B1 (de) | 2010-10-17 | 2016-05-25 | Yeda Research and Development Co. Ltd. | Verfahren und zusammensetzungen zur behandlung von insulinassoziierten erkrankungen |
EP2720720B1 (de) | 2011-06-14 | 2018-02-28 | Yeda Research and Development Co. Ltd. | Kombinationstherapie zur verhinderung von dcis-bildung und deren fortschreiten zu brustkrebs |
JP6063613B2 (ja) | 2011-08-09 | 2017-01-18 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ベータ細胞の分化およびインスリン産生を促進するためのmiR−7のダウンレギュレーション |
WO2013061328A2 (en) | 2011-10-27 | 2013-05-02 | Yeda Research And Development Co. Ltd. | Method of treating cancer |
WO2013076730A1 (en) | 2011-11-27 | 2013-05-30 | Yeda Research And Development Co. Ltd. | Methods of regulating angiogenesis and compositions capable of same |
EP3401394A1 (de) | 2012-02-22 | 2018-11-14 | Exostem Biotec Ltd | Erzeugung von neuralen stammzellen |
BR112015026702A2 (pt) | 2013-04-21 | 2018-02-06 | Yeda Res And Developmente Co Ltd | métodos de extermínio de células senescentes |
MX359191B (es) | 2013-07-19 | 2018-09-18 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
MX2016005778A (es) | 2013-11-04 | 2016-12-20 | Monsanto Technology Llc | Composiciones y metodos para controlar infestaciones de plagas y parasitos de los artropodos. |
CN111068053A (zh) | 2014-02-03 | 2020-04-28 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 使用酪蛋白激酶i抑制剂以消耗干细胞的用途 |
EP3125676A4 (de) | 2014-04-01 | 2018-02-14 | Monsanto Technology LLC | Zusammensetzungen und verfahren zur bekämpfung von insektenbefall |
EP3174982A4 (de) | 2014-07-29 | 2018-06-20 | Monsanto Technology LLC | Zusammensetzungen und verfahren zur bekämpfung von insektenbefall |
US11920164B2 (en) | 2014-07-30 | 2024-03-05 | Yeda Research And Development Co. Ltd. | Media for culturing naive human pluripotent stem cells |
WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
WO2016079736A2 (en) | 2014-11-17 | 2016-05-26 | Yeda Research And Development Co. Ltd. | Methods of treating diseases related to mitochondrial function |
RU2723049C2 (ru) | 2015-01-22 | 2020-06-08 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с leptinotarsa |
CA2977607A1 (en) | 2015-02-26 | 2016-09-01 | Jacob Schneiderman | Methods and compositions relating to leptin antagonists |
WO2016135732A1 (en) | 2015-02-26 | 2016-09-01 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
AU2016257871A1 (en) | 2015-05-04 | 2017-11-30 | Beeologics, Inc. | Compositions and methods for controlling arthropod parasite and pest infestations |
WO2016181393A1 (en) | 2015-05-11 | 2016-11-17 | Yeda Research And Development Co. Ltd. | Citrin inhibitors for the treatment of cancer |
WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
EA201792547A1 (ru) | 2015-05-21 | 2018-04-30 | Иеда Рисеч Энд Девелопмент Ко. Лтд. | Популяции бактерий для стимуляции состояния здоровья |
US11053495B2 (en) | 2015-07-17 | 2021-07-06 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
EP3331546B1 (de) | 2015-08-03 | 2023-10-04 | Biokine Therapeutics Ltd. | Cxcr4-antagonist zur behandlung von krebs |
IL289849B2 (en) | 2015-11-10 | 2024-01-01 | Nat Inst Biotechnology Negev Ltd | Means and methods for reducing the tumorigenicity of cancer stem cells |
JP2019505511A (ja) | 2016-01-06 | 2019-02-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 |
US11136597B2 (en) | 2016-02-16 | 2021-10-05 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
US20190216891A1 (en) | 2016-03-06 | 2019-07-18 | Yeda Research And Development Co., Ltd. | Method for modulating myelination |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
EP3658158A4 (de) | 2017-07-27 | 2021-04-14 | The National Institute for Biotechnology in the Negev Ltd. | Smac/yldiablo-inhibitoren zur behandlung von krebs |
IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
EP3723785A1 (de) | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Komplexe modulatoren des cop9-signalosoms (csn) und deren verwendung |
EP3749368A1 (de) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Verfahren zur identifizierung und verwendung von mitteln zur behandlung von mit darmbarrierefunktionsstörungen einhergehenden krankheiten |
CN112236131A (zh) | 2018-03-29 | 2021-01-15 | 技术研究及发展基金有限公司 | 包含pten抑制剂的囊泡及其用途 |
KR20210018267A (ko) | 2018-05-07 | 2021-02-17 | 알닐람 파마슈티칼스 인코포레이티드 | 간외 전달 |
WO2020170240A1 (en) | 2019-02-21 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
WO2020236600A1 (en) | 2019-05-17 | 2020-11-26 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
EP4004548A1 (de) | 2019-07-29 | 2022-06-01 | Yeda Research and Development Co. Ltd | Verfahren zur behandlung und diagnose von lungenkrebs |
WO2022011214A1 (en) | 2020-07-10 | 2022-01-13 | Alnylam Pharmaceuticals, Inc. | Circular sirnas |
EP4367237A2 (de) | 2021-07-09 | 2024-05-15 | Alnylam Pharmaceuticals, Inc. | Bis-rnai-verbindungen zur zns-verabreichung |
EP4384603A1 (de) | 2021-08-10 | 2024-06-19 | Gamida-Cell Ltd. | Manipulierte nk-zellen, verfahren zu deren herstellung und verwendungen davon |
WO2023220744A2 (en) | 2022-05-13 | 2023-11-16 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
-
1989
- 1989-12-19 CA CA002006008A patent/CA2006008C/en not_active Expired - Fee Related
- 1989-12-20 ES ES89313391T patent/ES2069598T3/es not_active Expired - Lifetime
- 1989-12-20 PT PT92640A patent/PT92640B/pt not_active IP Right Cessation
- 1989-12-20 JP JP2502252A patent/JPH04502407A/ja active Pending
- 1989-12-20 DE DE68921315T patent/DE68921315T2/de not_active Expired - Fee Related
- 1989-12-20 EP EP89313391A patent/EP0375408B1/de not_active Expired - Lifetime
- 1989-12-20 AU AU48384/90A patent/AU640910B2/en not_active Ceased
- 1989-12-20 WO PCT/US1989/005769 patent/WO1990006934A1/en not_active Application Discontinuation
- 1989-12-20 EP EP19900901460 patent/EP0449972A4/en active Pending
- 1989-12-20 AT AT89313391T patent/ATE118818T1/de not_active IP Right Cessation
-
1991
- 1991-06-20 DK DK911200A patent/DK120091D0/da not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2006008C (en) | 2000-02-15 |
DK120091A (da) | 1991-06-20 |
WO1990006934A1 (en) | 1990-06-28 |
CA2006008A1 (en) | 1990-06-20 |
ATE118818T1 (de) | 1995-03-15 |
EP0449972A1 (de) | 1991-10-09 |
PT92640A (pt) | 1990-06-29 |
ES2069598T3 (es) | 1995-05-16 |
DE68921315D1 (de) | 1995-03-30 |
JPH04502407A (ja) | 1992-05-07 |
AU640910B2 (en) | 1993-09-09 |
EP0449972A4 (en) | 1992-03-18 |
DE68921315T2 (de) | 1995-08-03 |
EP0375408A1 (de) | 1990-06-27 |
PT92640B (pt) | 1995-09-12 |
AU4838490A (en) | 1990-07-10 |
EP0375408B1 (de) | 1995-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK120091D0 (da) | Tripelstrenget nukleinsyre og anvendelse heraf | |
DE69627698D1 (de) | Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren | |
EP0828849A4 (de) | Oligonukleotidliganden mit hoher affinität für wachstumsfaktoren | |
ATE239090T1 (de) | Methode zum generieren von einzelsträngigen dna molekülen | |
US5403708A (en) | Methods and compositions for determining the sequence of nucleic acids | |
DK51092D0 (da) | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf | |
ATE106948T1 (de) | Verfahren zur amplifizierung von nukleinsäuren. | |
AU3728093A (en) | Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids | |
FI102387B1 (fi) | Menetelmä ribonukleiinihapon (RNA) valmistamiseksi | |
EP0331939A3 (de) | Verfahren und Zusammensetzungen zum Widerstand gegen Retroviralinfektionen | |
FI893526A0 (fi) | Material och metod foer oekning av nukleinsyrahybridisering. | |
DE69333073D1 (de) | Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen | |
EP0369360A3 (de) | Differenzierung von Nukleinsäure-Segmenten auf der Basis von Verschiedenheiten der Nukleotiden | |
ATE161587T1 (de) | Technik des genetischen fingerabdrucks mit dns- vervielfältigung | |
DE69133629D1 (de) | nssystem zur Bestimmung von genetischen Krankheiten | |
Slettan et al. | Isolation and characterization of variable (GT) n repetitive sequences from Atlantic salmon, Salmo salar L. | |
Collick et al. | Minisatellite binding protein Msbp-1 is a sequence-specific single-stranded DNA-binding protein | |
ATE317123T1 (de) | Reaktiver träger zur bestimmung von dna fragmenten | |
DE69626032D1 (de) | Modifizierung von oligonukleotid-primer-sequenzen zum manipilieren der zugabe von nicht-template-nukleotiden | |
HK74595A (en) | Specific nucleic-acid fragments of the human villin gene and their application to diagnostic ends | |
Holden | Map marks the X (chromosome) | |
James Shen | Superhetieity induces hypersensitivity of a human polypyrimldine polypurine DNA sequence in the human α2-α1 globin intergenic region to SI nudease digestion-high resolution mapping of the clustered cleavage sites | |
Austerberry | DEVELOPMENTALLY REGULATED DNA DELETION IN TETRAHYMENA THERMOPHILA. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AHS | Application shelved for other reasons than non-payment |